RESUMEN
The mercury ions in waste water have threatened public health and environmental protection. In this sense, novel materials with outstanding performances for removal of Hg2+ are imperative. Herein, we demonstrate a thiol-functionalized zirconium metal-organic cage (MOC-(SH)2) with excellent dispersion displays ideal properties for Hg2+ capture. MOC-(SH)2 exhibits the ability of removing Hg2+ in aqueous solutions with a capacity of 335.9 mgHg2+/gMOC-(SH)2, which surpasses that of classical Zr-based metal-organic framework Uio-66-(SH)2 by 1.89 folds. The higher loading capacity of MOC-(SH)2 is probably owing to the excellent dispersion of the discrete cage, which makes the accessibility of binding sites (thiol) easier. Additionally, 99.6% of Hg2+ can be effectively captured by MOC-(SH)2 with the concentration decreased from 5 to 0.02 ppm reaching the permissible limit for Hg2+, outperforming the performance of Uio-66-(SH)2. The excellent absorption property of MOC-(SH)2 is also achieved in terms of superior selectivity under the presence of competitive metal ions. Meanwhile, the regenerated MOC-(SH)2 can be reused without apparent loss of Hg2+ loading capacity. UV-vis absorption spectra, IR spectra and emission spectra further verified the strong chemical affinity between Hg2+ and the thiol of MOC-(SH)2. The study lays the groundwork for using Zr-MOCs in the removal of toxic metal ions and environmental sustainability.
RESUMEN
Circulating tumor cells (CTCs), which have stem cell-like characteristics, might play a crucial role in cancer metastasis. CD44 has been identified as gastric cancer (GC) stem cell (CSC) marker. Here, the prognostic significance of CD44-positive CTCs in GC patients was investigated. CTCs were detected in 27 of 45 GC patients. The presence of CTCs was significantly associated with lymph node metastasis, distant metastasis, and recurrence (P = 0.007, P = 0.035, and P = 0.035, resp.). Nineteen of the 27 CTC-positive patients had CD44-positive CTCs. These patients were more likely to develop metastasis and recurrence than patients with CD44-negative CTCs. CD44-positive CTC counts were higher in recurrent patients than in the nonrecurrent ones (means 4.8 and 1.9, resp.; P = 0.010). Furthermore, 13 of 19 patients with CD44-positive CTCs developed recurrent disease, and the mean time to recurrence was shorter than that in patients with CD44-negative CTCs (10.54 ± 5.55 and 19.13 ± 9.72 months, resp.; P = 0.04). COX proportional hazards model indicated that the presence of CD44-positive CTCs and TNM stage were independent predictors of recurrence for GC (P = 0.030 and 0.008). So identifying the stem cell-like CTC subset may provide more clinically useful prognostic information than only detecting CTCs.
